Vous êtes ici

Biocure Technology Inc.

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
CURE.X
Indice CSE: 
Devise: 

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.

Vous êtes ici

Biocure Technology Inc. (CURE.X)

SEDAR Information

Information d'entreprise

Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
Canada
Téléphone
604-609-7146
Fax
N/A
Courriel
admin@biocuretech.com
URL
http://www.biocuretech.com
Date d’inscription à la cote
Lundi, mai 10, 2010
Relations avec les investisseurs
n/a
Vérificateur
DMCL Chartered Professional Accountants

Capitalisation

Capitalisation: 
10444504
Réservé à l'émission: 
884059

Company Officers

Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer

Bulletins

23/10/2024

2024-1024 – Consolidation - Biocure Technology Inc. (CURE.X)

le 23 octobre/October 2024

Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every nine (9) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 10,444,504 common shares.

The name and symbol will not change.